嵌合抗原受体 T 细胞疗法治疗实体瘤：我们还有多远？系统文献回顾。
CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
机构信息
Faculty of Medicine, Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon.
Department of Urology, Hôpital Universitaire de Bruxelles, Hôpital Érasme, Université Libre de Bruxelles, Brussels, Belgium.
出版信息
Cancer Invest. 2022 Nov;40(10):923-937. doi: 10.1080/07357907.2022.2125004. Epub 2022 Sep 20.
This systematic review aims to assess all the prospective studies published to date on the efficacy of CAR-T cell therapy in solid tumors. Databases searched were PubMed and Google Scholar from inception through May 1st 2021. Search query was (Chimeric antigen receptor) or (CAR-T) or (T-CAR). Twenty-nine prospective studies (265 patients) were included. Most published clinical trials are phase I. Clinical benefit was 100% in epithelial ovarian cancer, 70-82% in gastrointestinal tumors, 79% in mesothelioma, 63% in small-cell lung cancer, 24-67% in sarcoma, 50-62% in prostate cancer, and 45-50% in central nervous system tumors. No serious CAR-T cell specific serious toxicities were noted.
本系统评价旨在评估迄今为止所有关于嵌合抗原受体 T 细胞（CAR-T）疗法在实体瘤中的疗效的前瞻性研究。检索的数据库为 PubMed 和 Google Scholar，检索时间从建库至 2021 年 5 月 1 日。检索词为（Chimeric antigen receptor）或（CAR-T）或（T-CAR）。共纳入 29 项前瞻性研究（265 例患者）。大多数已发表的临床试验为 I 期。上皮性卵巢癌的临床获益率为 100%，胃肠道肿瘤为 70-82%，间皮瘤为 79%，小细胞肺癌为 63%，肉瘤为 24-67%，前列腺癌为 50-62%，中枢神经系统肿瘤为 45-50%。未观察到严重的 CAR-T 细胞特异性严重毒性。
Zotero 插件